Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
- Author:
Miso KIM
1
;
Hyo Sup SHIM
;
Sheehyun KIM
;
In Hee LEE
;
Jihun KIM
;
Shinkyo YOON
;
Hyung-Don KIM
;
Inkeun PARK
;
Jae Ho JEONG
;
Changhoon YOO
;
Jaekyung CHEON
;
In-Ho KIM
;
Jieun LEE
;
Sook Hee HONG
;
Sehhoon PARK
;
Hyun Ae JUNG
;
Jin Won KIM
;
Han Jo KIM
;
Yongjun CHA
;
Sun Min LIM
;
Han Sang KIM
;
Choong-Kun LEE
;
Jee Hung KIM
;
Sang Hoon CHUN
;
Jina YUN
;
So Yeon PARK
;
Hye Seung LEE
;
Yong Mee CHO
;
Soo Jeong NAM
;
Kiyong NA
;
Sun Och YOON
;
Ahwon LEE
;
Kee-Taek JANG
;
Hongseok YUN
;
Sungyoung LEE
;
Jee Hyun KIM
;
Wan-Seop KIM
Author Information
- Publication Type:Review
- From:Journal of Pathology and Translational Medicine 2024;58(4):147-164
- CountryRepublic of Korea
- Language:EN
- Abstract: In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
